Cotter Gad, Cannon Christopher P, McCabe Carolyn H, Michowitz Yoav, Kaluski Edo, Charlesworth Andrew, Milo Olga, Bentley Jane, Blatt Alex, Krakover Rikardo, Zimlichman Reuven, Reisin Leonardo, Marmor Alon, Lewis Basil, Vered Zvi, Caspi Avi, Braunwald Eugene
Cardiology Institutes of Assaf-Harofeh Medical Center, Zerifin, Israel.
Am Heart J. 2003 Apr;145(4):622-7. doi: 10.1067/mhj.2003.6.
Cerebrovascular accidents (CVAs), transient ischemic attacks (TIAs), and peripheral arterial disease (PAD) frequently coexist with coronary artery disease (CAD) and were previously reported to adversely affect the prognosis of patients with chronic CAD.
We examined the effect of prior CVA/TIA or PAD (extra-cardiac vascular disease [EVD]) on the outcome of 10,281 patients with acute coronary syndromes enrolled in the Orbofiban in Patients with Unstable Coronary Syndromes-Thrombolysis in Myocardial Infarction (OPUS-TIMI) 16 trial of the oral glycoprotein IIb/IIIa antagonist orbofiban plus aspirin versus aspirin alone. We evaluated mortality, recurrent cardiac events, and stroke and used multivariate analysis to control for differences in baseline characteristics.
Patients with EVD were older, had more coronary risk factors, had a history of CAD, and received more intensive medical treatment at baseline. The acute event in these patients was more often unstable angina pectoris and less commonly Q-wave myocardial infarction. With coronary angiography, patients with prior EVD more often had multivessel disease. During the 10 months of follow-up, the presence of EVD was predictive of an increased hazard of death, reinfarction, recurrent ischemia, stroke, and a composite of these events. Despite the increased severity of the CAD and increased risk of events, patients with EVD were treated less frequently with beta-blockers and more frequently with calcium blockers. Despite patients with EVD having a 45% higher incidence of hypercholesterolemia, lipid-lowering agents were prescribed in a similar percentage of patients as patients without EVD.
In patients with acute coronary syndromes, the presence of prior CVA, TIA, or PAD is associated with more extensive CAD and worse outcome. These patients appear to receive less aggressive treatment, which may explain, at least in part, their worse outcome.
脑血管意外(CVA)、短暂性脑缺血发作(TIA)和外周动脉疾病(PAD)常与冠状动脉疾病(CAD)并存,此前有报道称它们会对慢性CAD患者的预后产生不利影响。
我们在口服糖蛋白IIb/IIIa拮抗剂orbofiban加阿司匹林与单用阿司匹林的不稳定冠状动脉综合征患者的orbofiban在心肌梗死溶栓治疗(OPUS-TIMI)16试验中,研究了既往CVA/TIA或PAD(心脏外血管疾病[EVD])对10281例急性冠状动脉综合征患者结局的影响。我们评估了死亡率、复发性心脏事件和中风,并使用多变量分析来控制基线特征的差异。
EVD患者年龄更大,有更多的冠状动脉危险因素,有CAD病史,且在基线时接受更强化的药物治疗。这些患者的急性事件更常为不稳定型心绞痛,较少为Q波心肌梗死。在冠状动脉造影检查中,既往有EVD的患者多支血管病变更为常见。在10个月的随访期间,EVD的存在预示着死亡、再梗死、复发性缺血、中风以及这些事件的综合风险增加。尽管CAD的严重程度增加且事件风险增加,但EVD患者使用β受体阻滞剂治疗的频率较低,而使用钙通道阻滞剂治疗的频率较高。尽管EVD患者高胆固醇血症的发生率高45%,但开具降脂药物的患者比例与无EVD的患者相似。
在急性冠状动脉综合征患者中,既往有CVA、TIA或PAD与更广泛的CAD及更差的结局相关。这些患者似乎接受的积极治疗较少,这可能至少部分解释了他们较差的结局。